$BCDA
BioCardia, Inc.

2020 Q2 Form 10-Q Financial Statement

#000143774920010860 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $27.00K $38.00K $216.0K
YoY Change -68.6% -82.41% 8.54%
Cost Of Revenue $0.00 $4.000K $106.0K
YoY Change -100.0% -96.23% -32.48%
Gross Profit $27.00K $34.00K $110.0K
YoY Change -125.71% -69.09% 161.9%
Gross Profit Margin 100.0% 89.47% 50.93%
Selling, General & Admin $1.377M $1.857M $1.631M
YoY Change -4.24% 13.86% -4.45%
% of Gross Profit 5100.0% 5461.76% 1482.73%
Research & Development $2.224M $2.786M $2.166M
YoY Change 0.23% 28.62% 10.79%
% of Gross Profit 8237.04% 8194.12% 1969.09%
Depreciation & Amortization $22.00K $22.00K $23.00K
YoY Change -15.38% -4.35% 4.55%
% of Gross Profit 81.48% 64.71% 20.91%
Operating Expenses $3.601M $4.643M $3.797M
YoY Change -1.53% 22.28% 3.69%
Operating Profit -$3.574M -$4.609M -$3.687M
YoY Change -5.0% 25.01% 1.85%
Interest Expense $0.00 $20.00K $20.00K
YoY Change -100.0% 0.0% -50.0%
% of Operating Profit
Other Income/Expense, Net $1.000K $15.00K $22.00K
YoY Change -91.67% -31.82% -38.89%
Pretax Income -$3.570M -$4.590M -$3.670M
YoY Change -4.8% 25.07% 2.51%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.573M -$4.594M -$3.665M
YoY Change -4.72% 25.35% 2.26%
Net Earnings / Revenue -13233.33% -12089.47% -1696.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$463.0K -$672.0K -$756.7K
COMMON SHARES
Basic Shares Outstanding 6.848M 6.848M 43.63M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.09M $2.590M $2.840M
YoY Change 2032.69% -8.8% -70.57%
Cash & Equivalents $11.09M $2.587M $2.838M
Short-Term Investments
Other Short-Term Assets $280.0K $450.0K $290.0K
YoY Change -34.88% 55.17% 3.57%
Inventory $118.0K
Prepaid Expenses
Receivables $214.0K $179.0K $287.0K
Other Receivables $520.0K $0.00 $0.00
Total Short-Term Assets $12.10M $3.219M $3.528M
YoY Change 950.0% -8.76% -65.43%
LONG-TERM ASSETS
Property, Plant & Equipment $154.0K $164.0K $175.0K
YoY Change -29.36% -6.29% 15.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K $54.00K $54.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.032M $1.165M $1.629M
YoY Change -34.02% -28.48% 690.78%
TOTAL ASSETS
Total Short-Term Assets $12.10M $3.219M $3.528M
Total Long-Term Assets $1.032M $1.165M $1.629M
Total Assets $13.13M $4.384M $5.157M
YoY Change 383.36% -14.99% -50.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.525M $1.108M $1.139M
YoY Change -6.21% -2.72% 54.34%
Accrued Expenses $132.0K $99.00K $596.0K
YoY Change -82.14% -83.39% 2.94%
Deferred Revenue $104.0K $104.0K $118.0K
YoY Change 0.0% -11.86%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $230.0K
YoY Change
Total Short-Term Liabilities $4.551M $4.510M $3.323M
YoY Change 11.93% 35.72% 56.67%
LONG-TERM LIABILITIES
Long-Term Debt $280.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.010M $1.160M $1.020M
YoY Change 13.48% 13.73% 1175.0%
Total Long-Term Liabilities $1.290M $1.160M $1.020M
YoY Change 44.94% 13.73% 1175.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.551M $4.510M $3.323M
Total Long-Term Liabilities $1.290M $1.160M $1.020M
Total Liabilities $5.837M $5.667M $4.339M
YoY Change 17.87% 30.61% 96.87%
SHAREHOLDERS EQUITY
Retained Earnings -$109.2M -$105.7M -$90.03M
YoY Change 16.49% 17.37% 18.47%
Common Stock $12.00K $7.000K $44.00K
YoY Change -72.73% -84.09% 15.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.291M -$1.283M $818.0K
YoY Change
Total Liabilities & Shareholders Equity $13.13M $4.384M $5.157M
YoY Change 383.36% -14.99% -50.47%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$3.573M -$4.594M -$3.665M
YoY Change -4.72% 25.35% 2.26%
Depreciation, Depletion And Amortization $22.00K $22.00K $23.00K
YoY Change -15.38% -4.35% 4.55%
Cash From Operating Activities -$2.350M -$2.993M -$2.465M
YoY Change 4.44% 21.42% -18.81%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $5.000K $55.00K
YoY Change -100.0% -90.91% 1000.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$5.000K -$55.00K
YoY Change -100.0% -90.91% 1000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.85M
YoY Change
NET CHANGE
Cash From Operating Activities -2.350M -2.993M -2.465M
Cash From Investing Activities 0.000 -5.000K -55.00K
Cash From Financing Activities 10.85M
Net Change In Cash 8.500M -2.998M -2.520M
YoY Change -467.97% 18.97% -17.0%
FREE CASH FLOW
Cash From Operating Activities -$2.350M -$2.993M -$2.465M
Capital Expenditures $0.00 $5.000K $55.00K
Free Cash Flow -$2.350M -$2.998M -$2.520M
YoY Change 7.31% 18.97% -17.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
763000
CY2019Q4 bcda Accrued Director Compensation Current
AccruedDirectorCompensationCurrent
648000
CY2020Q1 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2854000
CY2019Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2561000
CY2020Q1 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
753000
CY2019Q4 bcda Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
652000
CY2020Q1 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
511000
CY2019Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
519000
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000925741
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6848355
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
BioCardia, Inc.
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2020Q1 dei Trading Symbol
TradingSymbol
bcda
CY2020Q1 bcda Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
CY2020Q1 bcda Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
CY2020Q1 bcda Grant Liability Current
GrantLiabilityCurrent
624000
CY2019Q4 bcda Grant Liability Current
GrantLiabilityCurrent
630000
CY2020Q1 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
20000
CY2019Q1 bcda Increase Decrease In Current Operating Lease Liability
IncreaseDecreaseInCurrentOperatingLeaseLiability
CY2020Q1 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
-146000
CY2019Q1 bcda Increase Decrease In Non Current Operating Lease Liability
IncreaseDecreaseInNonCurrentOperatingLeaseLiability
126000
CY2020Q1 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
118000
CY2019Q1 bcda Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
105000
CY2020Q1 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
453000
CY2019Q4 bcda Prepaid Expense And Other Current Assets
PrepaidExpenseAndOtherCurrentAssets
642000
CY2020Q1 bcda Sharebased Compensation Arrangement By Sharebased Payment Award Remaining Weighted Average Award Vesting Period
SharebasedCompensationArrangementBySharebasedPaymentAwardRemainingWeightedAverageAwardVestingPeriod
P3Y
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1108000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
914000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
179000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
147000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
99000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
979000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
957000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104374000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103433000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
941000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
690000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
412000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
941000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
690000
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3271779
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
932327
CY2020Q1 us-gaap Assets
Assets
4384000
CY2019Q4 us-gaap Assets
Assets
7678000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
3219000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6378000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2587000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5585000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5358000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2838000
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2998000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2520000
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.36
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2435808
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2435808
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6848355
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6825183
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6848355
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6825183
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
104000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
102000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4000
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
106000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
4647000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
3903000
CY2020Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
689000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
691000
CY2020Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q1 us-gaap Depreciation
Depreciation
22000
CY2019Q1 us-gaap Depreciation
Depreciation
23000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
122000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
293000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2019Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2020Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
157000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-36000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2000
CY2019Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-23000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-189000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-160000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2993000
CY2020Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4000
CY2020Q1 us-gaap Inventory Net
InventoryNet
CY2019Q4 us-gaap Inventory Net
InventoryNet
4000
CY2020Q1 us-gaap Inventory Write Down
InventoryWriteDown
3000
CY2019Q1 us-gaap Inventory Write Down
InventoryWriteDown
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1122000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
649000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
473000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106000
CY2020Q1 us-gaap Liabilities
Liabilities
5667000
CY2019Q4 us-gaap Liabilities
Liabilities
5308000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4384000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7678000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4510000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4003000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2465000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4594000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3665000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4609000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3687000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2786000
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
150000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1016000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
468000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
614000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
158000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
153000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
947000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1065000
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1205
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y273D
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q1 us-gaap Other Operating Income
OtherOperatingIncome
16000
CY2019Q1 us-gaap Other Operating Income
OtherOperatingIncome
23000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1143000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1138000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
164000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2166000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105664000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101070000
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
38000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
216000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1505000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1857000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1631000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
941000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
690000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
472113
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.63
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16947
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
515036
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
31455
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
821464
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
835972
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.99
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.20
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.32
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.32
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.33
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
569000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y146D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y219D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y146D
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2370000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1283000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3792000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
817000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr><td style="vertical-align:top;width:6.7%;"></td> <td style="vertical-align:top;width:3.3%;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></td> <td colspan="2" style="vertical-align:top;width:90%;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></td> </tr> <tr> <td style="vertical-align:top;width:6.7%;">&nbsp;</td> <td style="vertical-align:top;width:3.3%;">&nbsp;</td> <td colspan="2" style="vertical-align:top;width:90%;">&nbsp;</td> </tr> <tr> <td style="vertical-align:top;width:6.7%;">&nbsp;</td> <td style="vertical-align:top;width:3.3%;">&nbsp;</td> <td colspan="2" style="vertical-align:top;width:90%;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, right-of-use assets and related liabilities, incremental borrowing rate, allowances for doubtful accounts and sales returns, derivative instruments, clinical accruals, and inventory valuation.</td> </tr> </table></div></div></div>
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6831976
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4248450

Files In Submission

Name View Source Status
0001437749-20-010860-index-headers.html Edgar Link pending
0001437749-20-010860-index.html Edgar Link pending
0001437749-20-010860.txt Edgar Link pending
0001437749-20-010860-xbrl.zip Edgar Link pending
bcda-20200331.xml Edgar Link completed
bcda-20200331.xsd Edgar Link pending
bcda-20200331_cal.xml Edgar Link unprocessable
bcda-20200331_def.xml Edgar Link unprocessable
bcda-20200331_lab.xml Edgar Link unprocessable
bcda-20200331_pre.xml Edgar Link unprocessable
bcda20200331_10q.htm Edgar Link pending
ex_181322.htm Edgar Link pending
ex_181323.htm Edgar Link pending
ex_181324.htm Edgar Link pending
ex_181325.htm Edgar Link pending
ex_186905.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending